Compare Inovio Pharmaceuticals Inc (INO) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Petróleo Brasileiro SA — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Petróleo Brasileiro SA trades at $25.43 (market cap $151.94B). The key difference: Petróleo Brasileiro SA is far larger — about 1354.3× Inovio Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Petróleo Brasileiro SA for 25 Days on average.
| INO | PBR | |
|---|---|---|
Market Cap | $112.19M | $151.94B |
Volume | 3,201,278 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $2.65 | $24.69 |
52-Week Low | $0.66 | $11.54 |
Typical Hold Time | 43 Days | 25 Days |
Enterprise Value | $83.51M | $212.36B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Petrobras (PBR) is trading at $25.16, up 4.88% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 6.24, net margin of 24.52%, and positive earnings surprises in recent quarters. Recent news highlights new oil discoveries and production growth initiatives, while technical indicators show overbought conditions with RSI above 80.
PBR offers attractive valuation metrics and strong profitability, but faces risks from political interference and commodity price volatility. Analyst consensus leans bullish with 50% buy ratings, though the current price exceeds the $22.33 consensus target. The company's expansion projects and LNG deals provide long-term growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
